Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

XOMA Corporation (XOMA)

20.55   -0.3 (-1.44%) 02-03 13:54
Open: 20.525 Pre. Close: 20.85
High: 21.06 Low: 20.3545
Volume: 52,065 Market Cap: 235(M)

Technical analysis

as of: 2023-02-03 2:21:23 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 24.84     One year: 27.45
Support: Support1: 17.64    Support2: 14.68
Resistance: Resistance1: 21.27    Resistance2: 23.51
Pivot: 21.57
Moving Average: MA(5): 20.65     MA(20): 21.24
MA(100): 18.72     MA(250): 20.49
MACD: MACD(12,26): 0.2     Signal(9): 0.5
Stochastic oscillator: %K(14,3): 28.4     %D(3): 33.5
RSI: RSI(14): 49.4
52-week: High: 32.09  Low: 15.68
Average Vol(K): 3-Month: 25 (K)  10-Days: 25 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ XOMA ] has closed above bottom band by 21.3%. Bollinger Bands are 19.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 20.91 - 20.99 20.99 - 21.07
Low: 19.97 - 20.06 20.06 - 20.15
Close: 20.7 - 20.85 20.85 - 20.99

Company Description

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Headline News

Thu, 02 Feb 2023
Congenital Hyperinsulinism Market: Analysis of Epidemiology ... - Digital Journal

Tue, 31 Jan 2023
Botulism Pipeline Report provides an analysis of 4+ key companies ... - Digital Journal

Tue, 24 Jan 2023
Amolyt Pharma inks research and option deal with XOMA - The Pharma Letter

Thu, 12 Jan 2023
Should You Sell XOMA Corp (XOMA) in Biotechnology Industry? - InvestorsObserver

Fri, 06 Jan 2023
XOMA Announces New Employment Inducement Grants Under ... - GlobeNewswire

Tue, 22 Nov 2022
XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 11 (M)
Shares Float 8 (M)
% Held by Insiders 0.6 (%)
% Held by Institutions 59.5 (%)
Shares Short 356 (K)
Shares Short P.Month 382 (K)

Stock Financials

EPS 0.77
EPS Est Next Qtl -0.19
EPS Est This Year -2.94
EPS Est Next Year -1.33
Book Value (p.s.) 7.69
Profit Margin (%) 45
Operating Margin (%) 49.2
Return on Assets (ttm) 8.6
Return on Equity (ttm) 14.6
Qtrly Rev. Growth 9.1
Gross Profit (p.s.) 3.35
Sales Per Share 3.62
EBITDA (p.s.) 1.78
Qtrly Earnings Growth 0
Operating Cash Flow 22 (M)
Levered Free Cash Flow 9 (M)

Stock Valuations

PE Ratio 26.34
PEG Ratio -0.8
Price to Book value 2.67
Price to Sales 5.67
Price to Cash Flow 10.45

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2016-10-17
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.